Investigational drug · Phase 2
TH9619
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Solid Tumor, Colorectal Cancer (CRC), Squamous Cell Carcinoma of Head and Neck.
Phase 2Last checked: Nov 19, 2026Latest source record: Jan 28, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
1 still active
All registered trials
1
Any phase or sponsor naming "TH9619"
First trial start
2025
Aug 22, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "TH9619", any sponsor or status.
Conditions studied
As listed on its trial records.
- Solid Tumor
- Colorectal Cancer (CRC)
- Squamous Cell Carcinoma of Head and Neck
- Non-Small Cell Lung Cancer (NSCLC)
- Gastrooesophageal Junction Cancer
- Gastric Cancer
Approved drugs for the same conditions: Non-small cell lung cancer · Small cell lung cancer · Colorectal cancer · Stomach and esophageal cancer · Head and neck cancer · Oncology · Gastroenterology and liver
Largest trials
Live from ClinicalTrials.gov: studies naming "TH9619" as an intervention, largest first.
One-carbon Therapeutics ABIndustry
NCT07151040 · 43 participants (planned) · Start Aug 22, 2025 · Primary completion Dec 2026
Drug: TH9619 · For: Solid Tumor; Colorectal Cancer (CRC); Squamous Cell Carcinoma of Head and Neck and 3 more
Sites: Villejuif, France; Barcelona, Spain; Madrid, Spain · 4 sites in all
Newest research
PubMed records naming it or its code names, newest first.
- Somatic Mutation Profile in Normal Tissue Adjacent to Tumor in Colorectal Carcinoma Patients: Functional Effect on Gene Expression and Potential Implications for Precision Medicine.
Jasmine F, Vasiljevs D, Almazan A, et al. · Cancers (Basel) 2026
- Targeting NFATc1-regulated MTHFD2 one-carbon metabolism to suppress sustained T-cell-mediated inflammation in rheumatoid arthritis.
Manolakou T, Shen J, Boddul S, et al. · Signal Transduct Target Ther 2026
- Folate trapping is lethal to cancer cells.
Rather GM · Chem Biol Drug Des 2023
- Formate overflow drives toxic folate trapping in MTHFD1 inhibited cancer cells.
Green AC, Marttila P, Kiweler N, et al. · Nat Metab 2023
Also in development for Solid Tumor
- BMS-986507BL-B01D1, Iza-brenPhase 351 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Non-small Cell Lung Cancer, Solid Tumor, Urothelial Carcinoma
- SintilimabIBI308Phase 321 trials
Innovent Biologics (Suzhou) Co. Ltd. · Hepatocellular Carcinoma, Solid Tumor, HCC - Hepatocellular Carcinoma
- IfebemtinibIN10018, BI853520Phase 311 trials
InxMed (Shanghai) Co., Ltd. · Solid Tumor, NSCLC, Solid Tumor Cancer
- JAB-21822Glecirasib Citrate, KRAS G12C inhibitorPhase 310 trials
Allist Pharmaceuticals, Inc. · Non-small Cell Lung Cancer, KRAS P.G12C, Solid Tumor
- FavezelimabMK-4280, MK-4820APhase 39 trials
Merck & Co. · Melanoma, Carcinoma, Renal Cell, Solid Tumors
- PD-1 monoclonal antibodyPhase 39 trials
Sichuan Baili Pharmaceutical Co., Ltd. · Nasopharyngeal Carcinoma (NPC), Non-small Cell Lung Cancer, Nasopharyngeal Carcinoma
- PD-1 inhibitorPhase 38 trials
BioAtla, Inc. · Advanced Solid Tumors, Gastric or Gastroesophageal Junction Adenocarcinoma, NSCLC (Advanced Non-small Cell Lung Cancer)
- RC148Phase 38 trials
RemeGen Co., Ltd. · Previously Untreated Locally Advanced (IIIB/IIIC) or Metastatic (IV) e Nsq NSCLC Without Actionable Genomic Alterations, Solid Tumor, Advanced Gastric or Gastroesophageal Junction Adenocarcinoma
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.